The European response to the WHO call to eliminate cervical cancer as a public health problem

Show full item record



Permalink

http://hdl.handle.net/10138/323339

Citation

Arbyn , M , Gultekin , M , Morice , P , Nieminen , P , Cruickshank , M , Poortmans , P , Kelly , D , Poljak , M , Bergeron , C , Ritchie , D , Schmidt , D , Kyrgiou , M , Van den Bruel , A , Bruni , L , Basu , P , Bray , F & Weiderpass , E 2021 , ' The European response to the WHO call to eliminate cervical cancer as a public health problem ' , International Journal of Cancer , vol. 148 , no. 2 , pp. 277-284 . https://doi.org/10.1002/ijc.33189

Title: The European response to the WHO call to eliminate cervical cancer as a public health problem
Author: Arbyn, Marc; Gultekin, Murat; Morice, Philippe; Nieminen, Pekka; Cruickshank, Maggie; Poortmans, Philip; Kelly, Daniel; Poljak, Mario; Bergeron, Christine; Ritchie, David; Schmidt, Dietmar; Kyrgiou, Maria; Van den Bruel, Ann; Bruni, Laia; Basu, Partha; Bray, Freddie; Weiderpass, Elisabete
Contributor: University of Helsinki, HUS Gynecology and Obstetrics
Date: 2021-01-15
Language: eng
Number of pages: 8
Belongs to series: International Journal of Cancer
ISSN: 0020-7136
URI: http://hdl.handle.net/10138/323339
Abstract: The age-standardised incidence of cervical cancer in Europe varies widely by country (between 3 and 25/100000 women-years) in 2018. Human papillomavirus (HPV) vaccine coverage is low in countries with the highest incidence and screening performance is heterogeneous among European countries. A broad group of delegates of scientific professional societies and cancer organisations endorse the principles of the WHO call to eliminate cervical cancer as a public health problem, also in Europe. All European nations should, by 2030, reach at least 90% HPV vaccine coverage among girls by the age of 15 years and also boys, if cost-effective; they should introduce organised population-based HPV-based screening and achieve 70% of screening coverage in the target age group, providing also HPV testing on self-samples for nonscreened or underscreened women; and to manage 90% of screen-positive women. To guide member states, a group of scientific professional societies and cancer organisations engage to assist in the rollout of a series of concerted evidence-based actions. European health authorities are requested to mandate a group of experts to develop the third edition of European Guidelines for Quality Assurance of Cervical Cancer prevention based on integrated HPV vaccination and screening and to monitor the progress towards the elimination goal. The occurrence of the COVID-19 pandemic, having interrupted prevention activities temporarily, should not deviate stakeholders from this ambition. In the immediate postepidemic phase, health professionals should focus on high-risk women and adhere to cost-effective policies including self-sampling.
Subject: cervical cancer screening
COVID-19
elimination of cervical cancer
Europe
HPV vaccination
WHO
QUALITY-ASSURANCE
NORDIC COUNTRIES
HPV INFECTION
VACCINE
PREVENTION
GUIDELINES
MORTALITY
EFFICACY
DISEASE
3122 Cancers
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
ijc.33189.pdf 812.4Kb PDF View/Open
The_European_re ... _public_health_problem.pdf 1.359Mb PDF View/Open

This item appears in the following Collection(s)

Show full item record